98%
921
2 minutes
20
Patients with obsessive compulsive disorder (OCD) randomised to sertraline, manualised cognitive behavioural therapy (CBT), or combination (sertraline + CBT), underwent cognitive assessment. Cognitive testing was conducted at baseline and at week 16. The stop signal reaction time task (SSRT) was used to evaluate motor impulsivity and attentional flexibility was evaluated using the intra/extra-dimensional set shifting task. Paired-samples t -tests or nonparametric variants were used to compare baseline and posttreatment scores within each treatment group. Forty-five patients were tested at baseline (sertraline n = 14; CBT n = 14; sertraline + CBT n = 17) and 23 patients at week 16 (sertraline n = 6; CBT n = 7; sertraline + CBT n = 10). The mean dosage of sertraline was numerically higher in those taking sertraline as a monotherapy (166.67 mg) compared with those taking sertraline in combination with CBT (100 mg). Analysis of pre-post treatment scores using an intent-to-treat-analysis found a significant reduction in the SSRT in those treated with sertraline, whilst there was no significant change on this task for those treated with CBT or the combination. This study found that motor inhibition improved significantly following sertraline monotherapy. Suboptimal sertraline dosing might explain the failure to detect an effect on motor inhibition in the group receiving combination of sertraline + CBT. Higher dose sertraline may have broader cognitive effects than CBT for OCD, motor impulsivity may have value as a measure of treatment outcome and, by extension, the SSRT could serve as a biomarker for personalising care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/YIC.0000000000000548 | DOI Listing |
Neuropsychopharmacology
September 2025
Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
This report sought to employ multi-modal integration of pre-treatment brain (electroencephalogram, resting-state functional magnetic resonance imaging) and blood (immune and metabolic) biomarkers to facilitate causal inference-based treatment selection by virtue of establishing predictability of remission to multi-stage antidepressant treatment. Data from two stages of pharmacotherapy in the 'Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression' (EMBARC) study from participants with both brain and blood biomarkers were included (N = 197). Participants were initially randomized to sertraline or placebo (Stage 1), and depending on clinical response at week-8, their therapy in Stage 2 was either maintained or switched (to sertraline, if a non-responder to placebo, or to bupropion, if a non-responder to sertraline).
View Article and Find Full Text PDFJACC Clin Electrophysiol
September 2025
Department of Cardiovascular Diseases, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Minnesota, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Ro
Background: Long QT syndrome (LQTS) is a potentially life-threatening genetic heart disease. Because many psychiatric medications have QT-prolonging potential, there is hesitation when prescribing them to LQTS patients with concomitant psychiatric disorders, which may lead to suboptimal mental health care.
Objectives: This study sought to evaluate the incidence of breakthrough cardiac events (BCEs) in patients with diagnosed and clinically treated LQTS on QT-prolonging psychiatric medications.
J Affect Disord
September 2025
Department of Traditional Chinese Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China. Electronic address:
Introduction: Dysfunction in amygdala networks has been implicated in major depressive disorder (MDD). Pharmacological treatments, such as esketamine and sertraline, are believed to exert their antidepressant effects by modulating amygdalar activity. This study aimed to investigate the relationship between changes in dynamic functional connectivity (dFC) within amygdala subregions and treatment outcomes, with a focus on identifying potential neuroimaging markers.
View Article and Find Full Text PDFJ Clin Neuromuscul Dis
September 2025
Department of Neurology, Mayo Clinic, Rochester, MN .
Objectives: Multiple acyl-coenzyme A dehydrogenase deficiency (MADD) is a rare, yet treatable, disorder of fatty acid β-oxidation with clinical presentations ranging from neonatal to very-late-onset forms. Very-late-onset MADD often has no identifiable genetic mutations and has been linked to sertraline exposure.
Methods: We report a case of very late-onset MADD with negative genetic testing, potentially associated with sertraline use.
Cureus
August 2025
General Internal Medicine and Nephrology, Robert Bosch Krankenhaus, Stuttgart, DEU.
Tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare autoimmune condition primarily affecting adolescents. Diagnosis is frequently delayed due to the nonspecific and temporally dissociated presentation of renal and ocular symptoms. We report the case of a 15-year-old girl who presented to her general practitioner with fatigue, polyuria, and recent weight loss.
View Article and Find Full Text PDF